Editorial Commentary


Molecular subtypes and response to immunotherapy in bladder cancer patients

Tilman Todenhöfer, Roland Seiler

Abstract

The introduction of immunotherapy for the treatment of patients with advanced urothelial carcinoma has led to a significant interest in markers predicting therapy response. As in other tumor entities, approximately 20% of patients show objective response to single drug checkpoint inhibition. The identification of these patients is of great interest in order to avoid ineffective and expensive treatment.

Download Citation